Inactive Instrument

ENTREMED Share Price Nasdaq

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
14/08	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	25.63L 22.54L 21.32L 19.33L 36.31L 25Cr 36.52L 2.55Cr 98.57L 13Cr 96.23L 94.15L 40Cr	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	2.44Cr 2.15Cr 2.03Cr 1.84Cr 3.46Cr 234.38Cr 3.48Cr 24Cr 9.39Cr 119.6Cr 9.17Cr 8.97Cr 384.33Cr	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.46%	Yield 2024 *	-	Yield 2025	-

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
14/08	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
21/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03/03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

14/08	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
01/07	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

ENTREMED Share Price Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news: ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.11%	+1.71%	+63.52%	+117.61%	1,05600Cr
JOHNSON & JOHNSON	+0.27%	+0.92%	+51.33%	+73.35%	66TCr
ABBVIE INC.	+0.73%	+0.68%	+20.70%	+74.90%	47TCr
ROCHE HOLDING AG	-0.39%	-2.33%	+38.85%	+41.98%	34TCr
NOVARTIS AG	+0.40%	+4.91%	+23.35%	+30.16%	28TCr
ASTRAZENECA PLC	+1.81%	+0.60%	+14.97%	+14.83%	26TCr
AMGEN INC.	+0.85%	+6.35%	+53.17%	+54.39%	23TCr
GILEAD SCIENCES, INC.	+0.85%	+1.10%	+35.78%	+101.82%	19TCr
NOVO NORDISK A/S	+0.01%	-2.28%	-28.05%	-60.72%	17TCr
Average	+0.41%	+0.97%	+30.40%	+49.81%	40.48TCr
Weighted average by Cap.	+0.14%	+1.04%	+40.65%	+70.07%

	2024	2025
Net sales	2.85Cr 2.51Cr 2.37Cr 2.15Cr 4.04Cr 273.93Cr 4.07Cr 28Cr 11Cr 139.78Cr 11Cr 10Cr 449.18Cr	2.07Cr 1.82Cr 1.72Cr 1.56Cr 2.93Cr 198.82Cr 2.95Cr 21Cr 7.97Cr 101.45Cr 7.78Cr 7.61Cr 326.01Cr
Net income	-3.93Cr -3.45Cr -3.26Cr -2.96Cr -5.56Cr -376.84Cr -5.59Cr -39Cr -15Cr -192.29Cr -15Cr -14Cr -617.93Cr	-4.81Cr -4.23Cr -4Cr -3.63Cr -6.81Cr -461.32Cr -6.85Cr -48Cr -18Cr -235.4Cr -18Cr -18Cr -756.45Cr
Net Debt	60.5L 53.21L 50.32L 45.64L 85.71L 58Cr 86.21L 6.02Cr 2.33Cr 30Cr 2.27Cr 2.22Cr 95Cr	2.19Cr 1.92Cr 1.82Cr 1.65Cr 3.1Cr 209.78Cr 3.11Cr 22Cr 8.4Cr 107.05Cr 8.2Cr 8.03Cr 343.99Cr